European S3-guidelines on the systemic treatment of psoriasis vulgaris.
Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considered.
Pathirana
D
D
Ormerod
A D
AD
Saiag
P
P
Smith
C
C
Spuls
P I
PI
Nast
A
A
Barker
J
J
Bos
J D
JD
Burmester
G-R
GR
Chimenti
S
S
Dubertret
L
L
Eberlein
B
B
Erdmann
R
R
Ferguson
J
J
Girolomoni
G
G
Gisondi
P
P
Giunta
A
A
Griffiths
C
C
Hönigsmann
H
H
Hussain
M
M
Jobling
R
R
Karvonen
S-L
SL
Kemeny
L
L
Kopp
I
I
Leonardi
C
C
Maccarone
M
M
Menter
A
A
Mrowietz
U
U
Naldi
L
L
Nijsten
T
T
Ortonne
J-P
JP
Orzechowski
H-D
HD
Rantanen
T
T
Reich
K
K
Reytan
N
N
Richards
H
H
Thio
H B
HB
van de Kerkhof
P
P
Rzany
B
B
D000068879:Adalimumab; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D011701:PUVA Therapy / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012176:Retinoids / Q000009:adverse effects / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D012176:Retinoids; D016572:Cyclosporine; D000069285:Infliximab; D000077944:Alefacept; D000068879:Adalimumab; D000068800:Etanercept; C472181:efalizumab; D008727:Methotrexate